Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

Steven P Vickers,1 Sharon C Cheetham,1 Katie R Headland,1 Keith Dickinson,1 Rolf Grempler,2 Eric Mayoux,2 Michael Mark,2 Thomas Klein2 1RenaSci, BioCity Nottingham, Nottingham, UK; 2Boehringer Ingelheim Pharma, Biberach an der Riss, Germany Abstract: The present study assessed the potential of the...

Full description

Bibliographic Details
Main Authors: Vickers SP, Cheetham SC, Headl, KR, Dickinson K, Grempler R, Mayoux E, Mark M, Klein T
Format: Article
Language:English
Published: Dove Medical Press 2014-07-01
Series:Diabetes, Metabolic Syndrome and Obesity
Online Access:http://www.dovepress.com/combination-of-the-sodium-glucose-cotransporter-2-inhibitor-empagliflo-a17427

Internet

http://www.dovepress.com/combination-of-the-sodium-glucose-cotransporter-2-inhibitor-empagliflo-a17427

Similar Items